{"id":"both-deferoxamine-mesylate-and-colchicine","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea (colchicine)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Injection site reactions (deferoxamine)"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Deferoxamine mesylate is an iron chelator that reduces labile iron and associated oxidative damage in cardiac tissue. Colchicine is an anti-inflammatory agent that inhibits microtubule polymerization and reduces inflammasome activation. Together, they aim to reduce iron-mediated oxidative stress and inflammation in acute heart failure, potentially improving cardiac function and reducing mortality.","oneSentence":"This combination uses deferoxamine to chelate iron and reduce oxidative stress, while colchicine suppresses inflammatory responses, together targeting myocardial injury and fibrosis in heart failure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:29.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute heart failure (Phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT06763055","phase":"PHASE3","title":"The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-02-27","conditions":"Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage, Supratentorial Intracerebral Haemorrhage","enrollment":2000},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Both deferoxamine mesylate and colchicine","genericName":"Both deferoxamine mesylate and colchicine","companyName":"The George Institute","companyId":"the-george-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses deferoxamine to chelate iron and reduce oxidative stress, while colchicine suppresses inflammatory responses, together targeting myocardial injury and fibrosis in heart failure. Used for Acute heart failure (Phase 3 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}